Aster Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.27K Sell
34
-2,423
-99% -$527K ﹤0.01% 819
2026
Q2
$601K Buy
2,457
+2,401
+4,288% +$521K 0.13% 233
2026
Q1
$6.53K Buy
+56
New +$9.7K ﹤0.01% 661
2025
Q3
– Sell
-37
Closed -$3.86K – 973
2025
Q2
$3.86K Buy
+37
New +$3.92K ﹤0.01% 894
2025
Q1
– Sell
-128
Closed -$10.8K – 1252
2024
Q4
$10.8K Buy
+128
New +$11.8K ﹤0.01% 752

Other funds holding AXSM

Aster Capital Management's AXSM Position: Q3 2026 in Review

Aster Capital Management reduced its Axsome Therapeutics (AXSM) stake by 99% in Q3 2026, selling an estimated $527K and leaving 34 shares worth $6.27K. The position accounts for ﹤0.01% of the portfolio, ranked #819.

Aster Capital Management first reported a position in AXSM in Q4 2024 and has held it in 5 quarters since. The position peaked at $601K in Q2 2026. 466 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Aster Capital Management held 34 shares of Axsome Therapeutics worth $6.27K as of Q3 2026.
  • Aster Capital Management sold 2,423 Axsome Therapeutics shares in Q3 2026, an estimated $527K.
  • Axsome Therapeutics made up ﹤0.01% of Aster Capital Management's portfolio in Q3 2026, its #819 holding.
  • Aster Capital Management first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Aster Capital Management's Axsome Therapeutics position peaked at $601K in Q2 2026.
  • 466 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Aster Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.